UnknownNot Applicable

Moderate Hypofractionated Radiotherapy for Lung Cancer

China60 participantsStarted 2016-11-01

Plain-language summary

The purpose of this study is to evaluate the incidences of Grade III and above radiation-reduced esophagitis and radiation-reduced pneumonia of patients with advanced lung cancer treated with moderate hypofractionated (3Gy/f) radiotherapy, and their predictors. Efficacies are also evaluated.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with previously untreated advanced lung cancer were recruited, who were confirmed pathologically or cytologically.
✓. The Karnofsky performance status (KPS) score ≥60.
✓. The expected survival time was≥3 months.
✓. The laboratory examination results showed a neutrophil count ≥2.0 × 109, a hemoglobin level ≥100 g/L, a platelet count ≥100 × 109, and enough liver and kidney functions.
✓. The patients did not show abnormal electrocardiogram (ECG) results.
✓. They did not have other combined diseases that required hospitalization.
✓. Informed consent required before enrollment.

Exclusion criteria

✕. Patients who were pregnant or breastfeeding.
✕. Patients who had another malignant tumor history (with the exception of patients with cervical carcinoma in situ and non-malignant melanoma skin cancer that had been clinically cured for at least 5 years), could not receive concurrent chemotherapy due to medical reasons.
✕. Superior vena cava syndrome.
✕. Syndrome and severe lung diseases that affected lung function were excluded.

What they're measuring

Incidence of grade III and above radiation-reduced esophagitis

Timeframe: three years

Incidence of grade III and above radiation-reduced pneumonitis

Timeframe: three years

Trial details

NCT IDNCT03833193

SponsorNorth China Petroleum Bureau General Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-05-01

Contact for this trial

QIANG LIN, Dr

+86-177-177-37955 billhappy001@163.com

View on ClinicalTrials.gov More Lung Cancer trials